### Edgar Filing: REPROS THERAPEUTICS INC. - Form 4

REPROS THI Form 4 February 15, 2	ERAPEUTICS II 2017	NC.										
										OMB APPROVAL		
Washington, D.C. 20549						OMB Number:	3235-0287					
Subject to Section 16. Form 4 or				CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						January 31, 2005 average rs per 0.5		
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).												
(Print or Type Re	esponses)											
			2. Issuer Name <b>and</b> Ticker or Trading Symbol REPROS THERAPEUTICS INC. [RPRX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Month				Date of Earliest Transaction onth/Day/Year) /13/2017				X Director Officer (give below)		o Owner er (specify		
			ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
THE WOOD	LANDS, TX 773	380						Form filed by M Person	Iore than One Re	eporting		
(City)	(State) (	Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactio Code (Instr. 8) Code V	4. Securiti on(A) or Dis (D) (Instr. 3, 4 Amount	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	02/13/2017			А	40,000	A	<u>(1)</u>	49,359	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

### Edgar Filing: REPROS THERAPEUTICS INC. - Form 4

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
Wyllie Michael 2408 TIMBERLOCH PLACE, SUITE I THE WOODLANDS, TX 77380	B-7 X							
Signatures								
/s/ Katherine A. Anderson, CPA	2/15/2017							

Date

### \*\*Signature of Reporting Person

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Consists of Restricted Stock Units (RSUs), representing the right to receive one share of the issuer's common stock for each vested RSU, (1) that were awarded on February 13, 2017 as compensation to non-employee members of the Board of Directors. The RSUs shall vest in thirty-six (36) equal increments on the last day of each calendar month from February 2017 through January 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.